Role of cortical and striatal 5-HT1A receptors in alleviating antipsychotic-induced extrapyramidal disorders

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 6, 2010, Pages 877-881

  Shimizu, Saki ^a   Tatara, Ayaka ^a   Imaki, Junta ^a   Ohno, Yukihiro ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

( )8 OH DPAT; 5 HT1A receptor; Extrapyramidal motor disorders; Microinjection; Motor cortex; MPTP; Striatum

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; HALOPERIDOL; N TERT BUTYL 3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 2 PHENYLPROPIONAMIDE; NEUROLEPTIC AGENT; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; DOPAMINE DERIVATIVE; PIPERAZINE DERIVATIVE; SEROTONIN ANTAGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CATALEPSY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DRUG MECHANISM; EXTRAPYRAMIDAL SYNDROME; MALE; MOTOR CORTEX; NERVE CELL LESION; NONHUMAN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; SYNAPSE; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; METABOLISM; MICROINJECTION; NERVE CELL; NONPARAMETRIC TEST; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CORPUS STRIATUM; HALOPERIDOL; HYDROXYDOPAMINES; MALE; MICROINJECTIONS; MOTOR CORTEX; NEURONS; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN ANTAGONISTS; STATISTICS, NONPARAMETRIC;

EID: 77955050229     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.04.005     Document Type: Article

References (37)

1. Alex K.D., Pehek E.A. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 2007, 113:296-320.
2. Antonelli T., Fuxe K., Tomasini M.C., Bartoszyk G.D., Seyfried C.A., Tanganelli S., et al. Effects of sarizotan on the corticostriatal glutamate pathways. Synapse 2005, 58:193-199.
3. Bishop C., Krolewski D.M., Eskow K.L., Barnum C.J., Dupre K.B., Deak T., et al. Contribution of the striatum to the effects of 5-HT1A receptor stimulation in l-DOPA-treated hemiparkinsonian rats. J Neurosci Res 2009, 87:1645-1658.
4. 1A agonists in the treatment of depression?. Biol Psychiatry 2003, 53:193-203.
5. Chartoff E.H., Ward R.P., Dorsa D.M. Role of adenosine and N-methyl-d-aspartate receptors in mediating haloperidol-induced gene expression and catalepsy. J Pharmacol Exp Ther 1999, 291:531-537.
6. 1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat. Neuropharmacology 2008, 55:1321-1328.
7. Hedlund P.B., Kelly L., Mazur C., Lovenberg T., Sutcliffe J.G., Bonaventure P. 8-OH-DPAT acts on both 5-HT1A and 5-HT7 receptors to induce hypothermiain rodents. Eur J Pharmacol 2004, 487:125-132.
8. Hussain N., Flumerfelt B.A., Rajakumar N. Glutamatargic regulation of haloperidol-induced c-fos expression in the rat striatum and nucleus accumbens. Neuroscience 2001, 102:391-399.
9. 2 adrenoceptor antagonism for antipsychotic-induced extrapyramidal motor disorders. Neurosci Lett 2009, 454:143-147.
10. Invernizzi R.W., Cervo L., Samanin R. 8-Hydroxy-2-(di-n-propylamino) tetralin, a selective serotonin1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis. Neuropharmacology 1988, 27:515-518.
11. 1A receptors. Biog Amines 2004, 18:307-317.
12. Kapur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996, 153:466-476.
13. 1A receptor activation in attenuation of catalepsy induction in rats. Neuropharmacology 2005, 49:135-143.
14. Korsgaard S., Gerlach J., Christensson E. Behavioral aspects of serotonin-dopamine interaction in the monkey. Eur J Pharmacol 1985, 118:245-252.
15. 1A receptor expression during memory formation. Psychopharmacology 2005, 181:309-318.
16. 1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine- generated lesions. Brain Res 2006, 1112:126-133.
17. Meltzer H.Y., Li Z., Kaneda Y., Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatr 2003, 27:1159-1172.
18. 1A receptors mediate an increase in locomotor activity in the monoamine-depleted rat. Psychopharmacology 2002, 163:85-94.
19. 1A receptors. J Pharmacol Exp Ther 2000, 295:853-861.
20. Neal-Beliveau B.S., Joyce J.N., Lucki I. Serotonergic involvement in haloperidol-induced catalepsy. J Pharmacol Exp Ther 1993, 265:207-217.
21. 2 receptor antagonist, using the mouse pole test. Pharmacol Biochem Behav 1994, 49:19-23.
22. 1A agonist, on activities of the lateral septal nucleus neurons in cats. Serotonin in the Central Nervous System and Periphery 1995, 159-165. Elsevier Science BV, Amsterdam. Y. Takada, G. Curzon (Eds.).
23. 2 receptor interaction in the atypical antipsychotic action of the novel succimide derivative, perospirone. Pol J Pharmacol 1997, 49:213-219.
24. 1A agonists using the mouse pole test. Prog Neuropsychopharmacol Biol Psychiatr 2008, 32:1302-1307.
25. Ohno Y., Shimizu S., Imaki J., Ishihara S., Sofue N., Sasa M., et al. Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens. Neuropharmacology 2008, 55:717-723.
26. 1A agonistic anxiolytic agent, on haloperidol-induced catalepsy and forebrain Fos expression in mice. J Pharmacol Sci 2009, 109:593-599.
27. Okuda K., Kotake Y., Ohta S. Parkinsonism-preventing activity of 1-methyl-1, 2, 3, 4-tetrahydroisoquinoline derivatives in C57BL mouse in vivo. Biol Pharm Bull 2006, 29:1401-1403.
28. Paxinos G., Watson C. The rat brain in stereotaxic coordinates. 2007, Elsevier, Massachusetts. 6th ed.
29. 1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur J Pharmacol 2002, 453:217-221.
30. 1A receptor: a representative member of the serotonin receptor family. Cell Mol Neurobiol 2005, 25:553-580.
31. 1A receptor: G protein coupling and signalling pathways. Br J Pharmacol 1999, 127:1751-1764.
32. 2 receptor effects of antipsychotics: bridging basic and clinical findings using PET. J Clin Psychiatry 1999, 60(Suppl. 10):15-19.
33. Samii A., Nutt J.G., Ransom B. Parkinson's disease. Lancet 2004, 363:1783-1793.
34. Tada K., Kasamo K., Ueda N., Suzuki T., Kojima T., Ishikawa K. Anxiolytic 5-hydroxytryptamine1A agonists suppress firing activity of dorsal hippocampus CA1 pyramidal neurons through a postsynaptic mechanism: single-unit study in unanesthetized, unrestrained rats. J Pharmacol Exp Ther 1999, 288:843-848.
35. Wadenberg ML., Hillegaart V. Stimulation of median, but not dorsal, raphe 5-HT1A autoreceptors by the local application of 8-OH-DPAT reverses raclopride-induced catalepsy in the rat. Neuropharmacology 1995, 34:495-499.
36. Wadenberg M.L., Young K.A., Richter J.T., Hicks P.B. Effects of local application of 5-hydroxytryptamine into the dorsal or median raphe nuclei on haloperidol-induced catalepsy in the rat. Neuropharmacology 1999, 38:151-156.
37. 1A agonist with antipsychotic- and antiparkinsonian-like properties. Neuropharmacology 2006, 51:129-140.